Plus   Neg

Perrigo Reaffirms FY19 Adj. EPS Outlook - Quick Facts

While reporting financial results for the second quarter, Perrigo Company plc (PRGO) on Thursday reaffirmed its adjusted earnings guidance for the full-year 2019, which includes the Ranir acquisition and Animal Health divestiture.

For fiscal 2019, the company continues to project adjusted earnings in the range of $3.75 to $4.05 per share.

On average, 13 analysts polled by Thomson Reuters expect the company to report earnings of $3.93 per share for the year. Analysts' estimates usually exclude special items.

The company said the guidance includes the Ranir acquisition and Animal Health divestiture, both of which closed in July as part of the company's portfolio reconfiguration to consumer self-care. The company also expects reported earnings in the range of $1.23 to $1.53 per share.

Additionally, the company said it expects an acceleration of net sales growth in the second half of the year driven by Ranir, excluding animal health, exited infant foods and impact of currency.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Food and Drug Administration has granted accelerated approval to Tazverik for the treatment of adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection. Epithelioid sarcoma is a rare sub-type of soft... STIHL recalls about 16,400 STIHL RE 90 pressure washers due to injury hazard. According to the company, the recalled pressure washer nozzle can disconnect from the spray wand when under pressure during use, posing an injury hazard. STIHL said it received seven reports of the nozzle detaching from... CVS Health Corp. launched 13 new HealthHUB locations in CVS Pharmacy stores across Philadelphia and South New Jersey. The healthcare company said it developed the HealthHUB store format to help people manage chronic conditions more conveniently and affordably. The store also features health and wellness products, clinical services and expertise.
Follow RTT